Navigation Links
Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia
Date:9/14/2008

Two newer atypical antipsychotic medications were no more effective than an older conventional antipsychotic in treating child and adolescent schizophrenia and may lead to more metabolic side effects, according to a new study funded by the National Institutes of Health's National Institute of Mental Health (NIMH). The study was published online ahead of print September 15, 2008, in the American Journal of Psychiatry.

"Schizophrenia and schizophrenia-related disorders are rare in childhood. But when they do occur, those afflicted generally have more severe symptoms and a worse prognosis than those who develop the disorder in adulthood," said NIMH Director Thomas R. Insel, M.D. "The newer atypical antipsychotics are often used to treat these children, but until now, it has been unclear how effective and safe they really are in children. The side effects of the newer medications should be factored into making treatment decisions."

The six-year, multisite Treatment of Early Onset Schizophrenia Study (TEOSS) included 116 youth between 8 and 19 years old, diagnosed with early onset schizophrenia spectrum disorder (EOSS). The TEOSS team randomly assigned the children to eight weeks of either olanzapine (Zyprexa) or risperidone (Risperdal)both new generation atypical antipsychoticsor to the older conventional antipsychotic molindone (Moban) plus benztropine, a medication often used to reduce side effects like uncontrolled shaking or tremor that can be associated with molindone. The children were monitored throughout the study by an NIMH oversight board to ensure their safety.

Response rates after eight weeks of treatment were comparable among the three medications50 percent of the children taking molindone improved, 46 percent taking risperidone improved, and 34 percent taking olanzapine improved. Children taking olanzapine or risperidone improved within the first two weeks, while the children on molindone improved within three weeks.

The treatment groups did differ in side effects. The children taking olanzapine gained about 13 pounds (6 kilograms) during the trial on average, while children taking risperidone gained about 8 pounds (3.6 kilograms), and those taking molindone did not gain weight. The olanzapine group also showed increases in cholesterol levels and other metabolic disruptions that may have become dangerous. The outcome prompted the safety review board to end the olanzapine arm of the study in 2006.

"Atypical antipsychotics are commonly used to treat kids with EOSS, but these results question the wisdom of that approach," said lead author Linmarie Sikich, M.D., of the University of North Carolina at Chapel Hill. "They also remind us that we need to develop safer, more effective medications to treat these children, given the limited effectiveness of both the atypical and the conventional medications."

Study coauthor Jeffery Lieberman, M.D., of Columbia University Medical Center, noted that TEOSS is the first documented evidence of how newer antipsychotics compare to older ones when treating children and adolescents with schizophrenia. "Doctors need to educate families about the potentially serious side effects these drugs can have so that strategies can be put into place to address them," he reiterated. The TEOSS results are similar to those found in the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), for which Lieberman was the principal investigator. CATIE found that the newer antipsychotics were no more effective than an older antipsychotic in treating adults with schizophrenia.


'/>"/>

Contact: Colleen Labbe
NIMHPress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
Source:Eurekalert

Related medicine news :

1. First generation antipsychotic drugs as effective as newer ones in some children
2. Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
3. Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
4. Newer Prostate Cancer Treatment Similar to Traditional Surgery
5. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
6. Newer Sedative Might Help Patients on Ventilators
7. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
8. Newer radiation treatment easier for some throat cancer patients
9. Newer Antibiotic Speeds TB Healing
10. Newer antidepressants led to less, not more, teen suicides
11. FDA Orders Warning Label on Older Antipsychotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made their ... to an ambitious venture that conjoined the passions of an NBA star, a Liberty ... Liberty community. These shoes will save lives from the rampant infections transmitted through the ...
(Date:8/18/2017)... York, NY (PRWEB) , ... August 18, 2017 ... ... launch of this summer’s edition of “Vision & Hearing,” advocating for active, healthy ... campaign focuses on resources available for individuals with hearing impairments and shares the ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez ... consultations to communities throughout the greater DC region, is inaugurating a “New Leash ... rescuing local animals and training them to be companions for veterans in need. ...
(Date:8/18/2017)... ... 18, 2017 , ... The Brian Gifford Agency, an Indiana-based firm providing asset ... of Campagna Academy in a charity drive to provide for at-risk children and teens ... Campagna Academy is a nonprofit organization that has offered critical programs to at-risk and ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active ... hormone replacement therapy and integrative medicine, has become a frontrunner for people seeking ... as menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/15/2017)... 15, 2017  AOTI Inc. announced today that its fully owned ... recently opened a New York City Office in Yonkers, ... unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This new ... for Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable ... Advanced ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: